Literature DB >> 30771118

Risk factors and control of seizures in 778 Chinese patients undergoing initial resection of supratentorial meningiomas.

Xiangrong Li1, Chengjun Wang1, Zhiqin Lin2, Meng Zhao1, Xiaohui Ren1, Xiaohui Zhang1, Zhongli Jiang3.   

Abstract

This retrospective study explored the risk factors for the occurrence of seizures in the pre- and postoperative period in patients undergoing supratentorial meningiomas surgery to investigate those who are likely to benefit from prophylactic antiepileptic drugs (AEDs). We reviewed the medical records of 778 supratentorial meningiomas patients who were operated at our institution between 2011 and 2012. A total of 100 (12.9%) patients experienced preoperative seizures; 41 patients (5.3%) experienced postoperative in-hospital seizures, and 91 (13.5%, n = 673) patients experienced postoperative seizures after discharge. Multivariate analysis revealed that motor cortex involvement (odds ratio [OR] 3.243, P < 0.001) and peritumoral edema ≥ 1 cm (OR 3.936, P < 0.001) were significant risk factors of preoperative seizures. Whereas presenting with headache (OR 0.259, P < 0.001) and age ≥ 55 years at surgery (OR 0.514, P = 0.009) showed decreased incidence of preoperative seizures. The involvement of motor cortex (OR 3.290, P = 0.003), postoperative Karnofsky Performance Scale (KPS) ≤ 70 (OR 5.389, P < 0.001), preoperative seizure (OR 4.003, P < 0.001), and occurrence of any medical/surgical complication (OR 3.925, P = 0.001) were significant risk factors for postoperative in-hospital seizures. Postoperative seizures after discharge were associated with tumor maximal diameter ≥ 3.5 cm (OR 1.903, P = 0.022), preoperative seizures (OR 4.350, P < 0.001), postoperative in-hospital seizures (OR 6.385, P < 0.001), and tumor recurrence/progression (OR 7.642, P < 0.001). The probability of seizure freedom in the 5-year follow-up was roughly 59% among patients with preoperative seizures, and 87% among patients without preoperative seizures. Cox regression analysis showed that tumor recurrence/progression (relative risk 2.987, 95% CI 1.517, 5.879, P = 0.002) was the only predictor of postoperative seizures in patients without a history of preoperative epilepsy. The use of postoperative prophylactic antiepileptic drug (AED) did not reduce the incidence of seizures in our analysis. Understanding the risk factors for seizures might help clinicians to predict their occurrence and develop effective anti-epileptic treatment strategies. Further prospective randomized controlled trials are needed to determine the risk factors for seizures and the efficacy of AED prophylaxis.

Entities:  

Keywords:  Antiepileptic drug; Risk factors; Seizure; Supratentorial meningioma; Surgery

Year:  2019        PMID: 30771118     DOI: 10.1007/s10143-019-01085-5

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  28 in total

Review 1.  Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy.

Authors:  Ricardo J Komotar; Daniel M S Raper; Robert M Starke; J Bryan Iorgulescu; Philip H Gutin
Journal:  J Neurosurg       Date:  2011-06-03       Impact factor: 5.115

Review 2.  Focused review on seizures caused by meningiomas.

Authors:  Peter Baumgarten; Mana Sarlak; Gabriela Baumgarten; Gerhard Marquardt; Volker Seifert; Adam Strzelczyk; Felix Rosenow; Thomas M Freiman
Journal:  Epilepsy Behav       Date:  2018-09-27       Impact factor: 2.937

3.  The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas.

Authors:  Michael E Sughrue; Ari J Kane; Gopal Shangari; Martin J Rutkowski; Michael W McDermott; Mitchel S Berger; Andrew T Parsa
Journal:  J Neurosurg       Date:  2010-04-09       Impact factor: 5.115

4.  Long-term control and predictors of seizures in intracranial meningioma surgery: a population-based study.

Authors:  Hai Xue; Olafur Sveinsson; Jiri Bartek; Petter Förander; Simon Skyrman; Lars Kihlström; Raana Shafiei; Tiit Mathiesen; Torbjörn Tomson
Journal:  Acta Neurochir (Wien)       Date:  2018-01-11       Impact factor: 2.216

5.  Recurrence of meningiomas.

Authors:  F Yamasaki; H Yoshioka; S Hama; K Sugiyama; K Arita; K Kurisu
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

6.  Postoperative seizure control in patients with tumor-associated epilepsy.

Authors:  Andrew Neal; Andrew Morokoff; Terence John O'Brien; Patrick Kwan
Journal:  Epilepsia       Date:  2016-09-26       Impact factor: 5.864

Review 7.  Antiepileptic drugs as prophylaxis for post-craniotomy seizures.

Authors:  Jennifer Pulman; Janette Greenhalgh; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 8.  Seizures in supratentorial meningioma: a systematic review and meta-analysis.

Authors:  Dario J Englot; Stephen T Magill; Seunggu J Han; Edward F Chang; Mitchel S Berger; Michael W McDermott
Journal:  J Neurosurg       Date:  2015-12-04       Impact factor: 5.115

9.  Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures.

Authors:  A Jacoby; C Gamble; J Doughty; A Marson; D Chadwick
Journal:  Neurology       Date:  2007-04-10       Impact factor: 9.910

10.  Glutamate release by primary brain tumors induces epileptic activity.

Authors:  Susan C Buckingham; Susan L Campbell; Brian R Haas; Vedrana Montana; Stefanie Robel; Toyin Ogunrinu; Harald Sontheimer
Journal:  Nat Med       Date:  2011-09-11       Impact factor: 53.440

View more
  7 in total

Review 1.  Meningioma Related Epilepsy- Pathophysiology, Pre/postoperative Seizures Predicators and Treatment.

Authors:  Rasha Elbadry Ahmed; Hailiang Tang; Anthony Asemota; Lei Huang; Warren Boling; Firas Bannout
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  Prophylactic AEDs Treatment for Patients With Supratentorial Meningioma Does Not Reduce the Rate of Perioperative Seizures: A Retrospective Single-Center Cohort Study.

Authors:  Ming Yang; Yong-Ran Cheng; Meng-Yun Zhou; Ming-Wei Wang; Lan Ye; Zu-Cai Xu; Zhan-Hui Feng; Xun-Tai Ma
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

Review 3.  Chinese guideline on the application of anti-seizure medications in the perioperative period of supratentorial craniocerebral surgery.

Authors:  Shuli Liang; Xing Fan; Feng Chen; Yonghong Liu; Binghui Qiu; Kai Zhang; Songtao Qi; Guojun Zhang; Jinfang Liu; Jianguo Zhang; Jun Wang; Xiu Wang; Ziyang Song; Guoming Luan; Xuejun Yang; Rongcai Jiang; Hua Zhang; Lei Wang; Yongping You; Kai Shu; Xiaojie Lu; Guoyi Gao; Bo Zhang; Jian Zhou; Hai Jin; Kaiwei Han; Yiming Li; Junji Wei; Kun Yang; Gan You; Hongming Ji; Yuwu Jiang; Yi Wang; Zhiguo Lin; Yan Li; Xuewu Liu; Jie Hu; Junming Zhu; Wenling Li; Yongxin Wang; Dezhi Kang; Hua Feng; Tinghong Liu; Xin Chen; Yawen Pan; Zhixiong Liu; Gang Li; Yunqian Li; Ming Ge; Xianming Fu; Yuping Wang; Dong Zhou; Shichuo Li; Tao Jiang; Lijun Hou; Zhen Hong
Journal:  Ther Adv Neurol Disord       Date:  2022-08-16       Impact factor: 6.430

4.  Brain infarction following meningioma surgery-incidence, risk factors, and impact on function, seizure risk, and patient-reported quality of life.

Authors:  Per S Strand; Lisa M Sagberg; Sasha Gulati; Ole Solheim
Journal:  Neurosurg Rev       Date:  2022-07-28       Impact factor: 2.800

5.  Meningioma preceding CASPR2 antibody limbic encephalitis with a stroke mimic: A case report.

Authors:  Xiao-Jin Lu; Ran Li; Yong-Xing Chen; Xian-Kai Xu; Bao-Lin Shi
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

Review 6.  Health-related quality of life in meningioma.

Authors:  Sameah Haider; Martin J B Taphoorn; Katharine J Drummond; Tobias Walbert
Journal:  Neurooncol Adv       Date:  2021-06-26

7.  Safety of intravenous tranexamic acid in patients undergoing supratentorial meningiomas resection: protocol for a randomised, parallel-group, placebo control, non-inferiority trial.

Authors:  Shu Li; Xiang Yan; Ruowen Li; Xingyue Zhang; Tingting Ma; Min Zeng; Jia Dong; Juan Wang; Xiaoyuan Liu; Yuming Peng
Journal:  BMJ Open       Date:  2022-02-02       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.